Immune reconstitution and remission in CML Journal Article


Author: Scheinberg, D. A.
Article Title: Immune reconstitution and remission in CML
Abstract: In a comprehensive and provocative report in this issue of Blood, with findings that were not necessarily expected, Hughes and colleagues report on the immune reconstitution that occurs as a consequence of the deepening remission achieved by patients with chronic myelogenous leukemia (CML) on tyrosine kinase inhibitors (TKIs). A significant fraction of patients with CML treated with BCR-ABL TKI achieve long-term remissions and maintain this state even after stopping the TKI. Why is this? Although the TKI itself may be contributing to this immune restoration, it is not entirely responsible as best effects are observed in those patients no longer on these drugs.1 © 2017 by The American Society of Hematology.
Journal Title: Blood
Volume: 129
Issue: 9
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-03-02
Start Page: 1064
End Page: 1065
Language: English
DOI: 10.1182/blood-2017-01-761569
PROVIDER: scopus
PUBMED: 28254822
DOI/URL:
Notes: Note -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric Score
MSK Authors